Marco Bono

Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge

Marco Bono, Daniele Fanale, Lorena Incorvaia et al. · ESMO Open · 2021 · 67 citations · Full text

Life Sciences, Genetics, Oncology +17

<i>BRCA1/2</i> pathogenic variants in triple-negative <i>versus</i> luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients

Lorena Incorvaia, Daniele Fanale, Marco Bono et al. · Therapeutic Advances in Medical Oncology · 2020 · 64 citations · Full text

Medicine, Genetics, Oncology +17

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2

Daniele Fanale, Lorena Incorvaia, Clarissa Filorizzo et al. · Cancers · 2020 · 57 citations · Full text

Life Sciences, Genetics, Oncology +17

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming

Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti et al. · Cancers · 2020 · 56 citations · Full text

Medicine, Immunology, Oncology +17

Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)—Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes

Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti et al. · Cancers · 2020 · 40 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14